相关实验视频
Updated: May 11, 2026

09:28
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Published on: November 25, 2014
氨酸通过抑制子阴道 afferent神经元中超极化后缓慢的后增高来增强神经刺激性
H R Middlekauff1, A Doering, J N Weiss
1Cardiovascular Research Laboratory, Departments of Medicine (Cardiology) and Physiology, Los Angeles, CA, USA. hmiddlek@medicine.medsch.ucla.edu
Circulation
|March 10, 2001
概括
氨酸通过阻断缓慢的超极化后 (AHPs) 来增强阴道神经元刺激性. 这种效应由A(2A) - 腺素受体介导,可能是通过增加cAMP的产生,而不是通道抑制.
科学领域:
- 神经科学是一个神经科学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 腺激活心脏附属神经元的电生理机制尚不清楚.
- 缓慢的超极化后 (AHP) 在阴道C纤维中降低神经元刺激性.
- 了解腺在神经元信号传递中的作用对于心血管研究至关重要.
研究的目的:
- 通过抑制缓慢的AHPs,研究腺是否会增加阴道神经元刺激性.
- 为了确定负责这些效应的特定腺受体亚型.
主要方法:
- 在培养的成年子结节质细胞上利用穿孔补丁技术.
- 刺激神经元与当前脉冲列车一起评估动作潜能响应率.
- 应用了腺和选择性腺受体激动剂/对抗剂,以评估对缓慢的AHP和兴奋力的影响.
主要成果:
- 腺素 (10μmol/L) 显著抑制缓慢的AHP,并将行动潜能响应率从3.8%提高到28%.
- 甲二氨酸受体激动剂NECA,但不是甲一氨酸受体激动剂CCPA,模仿了腺的作用.
- 甲基抗剂ZM 241385阻断了腺的作用,而甲基抗剂DPCPX没有.
结论:
- 氨酸有效地抑制缓慢的神经关神经元中的AHP.
- 氨酸2A受体是这种效应的主要媒介.
- 增加cAMP的产生,而不是I(Ca) 抑制,是腺的作用背后的可能机制.
相关概念视频
Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

